share_log

恒瑞医药(600276.SH):公司药品纳入国家医保目录

Jiangsu Hengrui Pharmaceuticals (600276.SH): The company's pharmaceuticals are included in the national medical insurance catalog.

Gelonghui Finance ·  Nov 28 15:35

On November 28, Gelonghui reported that jiangsu hengrui pharmaceuticals (600276.SH) announced that through medical insurance negotiations, fumaric acid tegilide injection, otamazolam capsules, and metformin sustained-release tablets (I)(II) have been included for the first time in the national medical insurance catalog; fluzoparib capsules have new indications added to the national medical insurance catalog through simplified renewal rules; injection of carelizumab has successfully renewed and added new indications to the national medical insurance catalog through simplified renewal rules; hydroxyethyl sulfonic acid darsiil tablets, revlimid tablets, and pregabalin sustained-release tablets have been retained in the national medical insurance catalog after successful renewal through simplified renewal rules; proline metformin tablets have successfully renewed and new indications have been retained in the national medical insurance catalog; ondansetron oral soluble film has successfully renewed and retained in the national medical insurance catalog; and the injection of esketamine hydrochloride and dexmedetomidine nasal spray have been adjusted to regular directory management.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment